



**Focused on
Growth and Innovation**

Half-year results 2023

Webcast presentation

August 15, 2023



David Veitch

Chief Executive Officer

Introduction



Disclaimer and forward-looking statements

This communication, including the accompanying oral presentation, contains certain forward-looking statements, including, without limitation, statements containing the words “believes”, “anticipates”, “expects”, “supposes”, “considers”, and words of similar import, or which can be identified as discussions of strategy, plans or intentions. Such forward-looking statements are based on the current expectations and belief of company management, and are subject to numerous risks and uncertainties, which may cause the actual results, financial condition, performance, or achievements of Basilea, or the industry, to be materially different from any future results, performance, or achievements expressed or implied by such forward-looking statements. Such factors include, among others, the following: the uncertainty of pre-clinical and clinical trials of potential products, limited supplies, future capital needs and the uncertainty of additional funding, compliance with ongoing regulatory obligations and the need for regulatory approval of the company’s operations and potential products, dependence on licenses, patents, and proprietary technology as well as key suppliers and other third parties, including in preclinical and clinical trials, acceptance of Basilea’s products by the market in the event that they obtain regulatory approval, competition from other biotechnology, chemical, and pharmaceutical companies, attraction and retention of skilled employees and dependence on key personnel, and dependence on partners for commercialization of products, limited manufacturing resources, management’s discretion as to the use of proceeds, risks of product liability and limitations on insurance, uncertainties relating to public health care policies, adverse changes in governmental rules and fiscal policies, changes in foreign currency and other factors referenced in this communication. Given these uncertainties, prospective investors are cautioned not to place undue reliance on such forward-looking statements. Basilea disclaims any obligation to update any such forward-looking statements to reflect future events or developments, except as required by applicable law.

HY 2023 – Key achievements

Zevtera

NDA submission in August 2023

Cresemba

- 14% y-o-y increase of global in-market sales to > USD 393 mn*
- Launched in Japan

Financial Performance


- 57% y-o-y increase in Cresemba & Zevtera related revenue
- Operating profit of CHF 36.9 mn
- Net profit of CHF 31.9 mn

Financial strength

- Increase of mid-year cash position to CHF 112.9 mn
- Net financial debt reduction by CHF 22 mn to CHF 38.1 mn

*MAT Q1/2023 vs. Q1/2022; MAT: Moving annual total; Source: IQVIA Analytics Link, March 2023

Potential for sustainable growth and value creation



1 The registration status and approved indications may vary from country to country.

2 Phase 3 program was funded in part with federal funds from the US Department of Health and Human Services (HHS); Administration for Strategic Preparedness and Response (ASPR); Biomedical Advanced Research and Development Authority (BARDA).

Adesh Kaul


Chief Financial Officer

Commercial & financial update



Cresemba continues strong in-market sales uptake

Sales in USD mn




> USD 393 mn
in-market
sales in the
12 months to
March 2023

MAT: Moving annual total; Source: IQVIA Analytics Link, March 2023

Significant growth potential for Cresemba

- USD 2.8 bn sales of best-in-class antifungals* (MAT Q1 2023)
- Recently launched in Japan and China, representing 25% of global potential

* Best-in-class antifungals: Cresemba (isavuconazole), posaconazole, voriconazole, AmBisome, anidulafungin, caspofungin, micafungin




MAT: Moving annual total; Source: IQVIA Analytics Link, March 2023

Strong financial half-year results 2023


In CHF mn	H1 2023	H1 2022
Cresemba & Zevtera related revenue	80.5	51.2
Royalty income	36.7	28.9
Total revenue	84.9	57.6
Cost of products sold	10.0	14.9
Operating expenses	38.0	52.8
Operating profit/loss	36.9	(10.0)
Net profit/loss	31.8	(12.2)

Note: Consistent rounding was applied.

Cresemba & Zevtera related revenue breakdown (in CHF mn)




Cash flows from operating activities (in CHF mn)



Note: Consolidated figures in conformity with US GAAP; rounding applied consistently

Continued reduction of debt level (in CHF mn)



Note: Figures as of the beginning of the fiscal year; rounding applied consistently

Increased revenue and profit guidance for FY 2023

In CHF mn	FY 2022	FY 2023* (previous guidance)	FY 2023* (new guidance)
Cresemba & Zevtera related revenue	122.3	145 – 148	147 – 150
Royalty income	65.0	~74	~76
Total revenue	147.8	155 – 158	157 – 160
Cost of products sold	24.6	25 – 28	25 – 27
Operating expenses	104.6	~80	~80
Operating profit	18.5	45 – 50	50 – 55
Net profit	12.1	36 – 41	41 – 46

*Excluding the impact of in-licensing activities

Note: Consistent rounding was applied.

Marc Engelhardt

Chief Medical Officer

Portfolio update



Antibacterial

Zevtera[®] (ceftobiprole)

Severe bacterial infections



basilea

Zevtera[®] 500 mg

powder for concentrate for solution for infusion.
Ceftriaxone (as ceftriaxone medocaril sodium).

*Each vial contains 500 mg of ceftriaxone,
equivalent to 666.6 mg of ceftriaxone medocaril sodium.*

For intravenous use after reconstitution and dilution.
Read the package leaflet before use.


10 vials

Ceftobiprole — Place in therapy


- Excellent treatment option in difficult-to-treat patients presenting to the hospital with severe infections, especially when the clinician suspects involvement of Gram-positive pathogens including *Staphylococcus aureus*
- Single agent first-line bactericidal broad-spectrum therapy with proven efficacy in SAB, ABSSSI and CABP, enabling to treat these vulnerable patients effectively early in their disease to achieve recovery
- Ceftobiprole is differentiated versus competitors in various clinically important aspects, including:
 - The strong, bactericidal activity against MSSA and MRSA
 - A robust Gram-negative coverage
 - Efficacy demonstrated in pulmonary infections in phase 3 studies
 - The safety profile reflecting the cephalosporin class
 - The low propensity for resistance development

The hospital anti-MRSA antibiotic market — A USD 2.6 bn market* with the US being the most important region

Daptomycin sales by region
(2015, before LOE)



Ceftaroline sales by region
(MAT Q1 2023)



* Vancomycin, linezolid, teicoplanin, daptomycin, tigecycline, telavancin, ceftaroline, dalbavancin, ceftobiprole, oritavancin and tedizolid (daptomycin and tigecycline are partial sales in the US in IQVIA data)

MRSA: Methicillin-resistant *Staphylococcus aureus*; LOE: Loss of exclusivity; ROW: Rest Of World; MAT: Moving annual total; Source: IQVIA Analytics Link, March 2023

Ceftobiprole — Strategy for accessing the US market

- NDA submitted in August 2023 for three indications:
 1. *Staphylococcus aureus* bacteremia (SAB)¹
 2. Acute bacterial skin and skin structure Infections (ABSSSI)²



3. Previously completed phase 3 study in community-acquired bacterial pneumonia (CABP) as a third indication³

- Phase 3 program largely funded by BARDA (~USD 112 million, or approximately 75 percent of the costs related to the SAB and ABSSSI phase 3 studies, regulatory activities and non-clinical work)
- Commercialization planned through partnership
 - Partnership to be secured prior to regulatory decision



¹ Holland TL et al., Open Forum Infect. Dis. 2022, 9: (S931–S932).


² Overcash JS et al. Clin Infect Dis. 2021;73:e1507-e1517.

³ Nicholson SC et al. International Journal of Antimicrobial Agents 2012 (39), 240-246.

FDA's NDA review process for a Qualified Infectious Disease Product

Ceftobiprole was granted QIDP status for SAB, ABSSSI and CABP

QIDP status provides 6 month priority review and extends market exclusivity to 10 years




Focused launch in area of highest unmet medical need with opportunities for broader utilization

Patient numbers in the United States

- *Staphylococcus aureus* bacteremia (SAB): 120,000 cases¹
- Acute bacterial skin and skin structure Infections (ABSSSI): >600,000 hospitalizations per year²
- Community-acquired bacterial pneumonia (CABP): >1,500,000 hospitalizations per year³

1. Kourtis AP et al. MMWR Morb Mortal Wkly Rep. 2019;68:214-219.
2. Edelsberg J et al. Emerg Infect Dis. 2009;15:1516-8.
3. Ramirez JA et al. Clin Infect Dis. 2017;65:1806-1812.



Antifungal

Cresemba® (isavuconazole)

Invasive mold infections



Cresemba pediatric development

- A pediatric development plan comprising 2 clinical studies was agreed with the FDA and the EMA
- Successful completion of the plan potentially results in 2 years additional market exclusivity in Europe and 6 months additional market exclusivity in the USA
- Clinical studies were undertaken in collaboration with Basilea's US partner Astellas and completed enrollment in August 2022
- Pediatric label extension in US/Europe is expected in 2023/2024, which would subsequently extend market exclusivity to Sep/Oct 2027

David Veitch

Chief Executive Officer

Outlook



Key milestones

Product	H1 2023	H2 2023	H1 2024
Ceftobiprole (Zevtera)		US NDA submission (August) ✓	Regulatory decision in the US (Q2)
			Executing US partnership (before regulatory decision)
Isavuconazole (Cresemba)	Launched in Japan ✓	Pediatric submission	

Increasing Cresemba & Zevtera revenue

In-licensing of anti-infectives (2023 and beyond)

Advancement of preclinical anti-infective assets

In-licensing focus



Partner of choice in the anti-infectives space

- ✓ Strong and proven R&D capabilities to bring drugs from research to market
- ✓ Cost-effective business model
- ✓ Experience in accessing non-dilutive funding incentives
- ✓ Financial strength and strong cash flow generation from commercialized brands

Antifungals

- Novel mechanisms of action
- Addressing areas of highest unmet medical needs
- Gaining benefits through orphan drug pathways
- Novel formulations

Commonalities

- Addressing serious hospital infections with increasing medical need
- Innovative & differentiated assets with potential for successful commercialization
- In-licensing assets from late stage research through to end of phase 2

Antibacterials

- Traditional and non-traditional approaches
- Potential for demonstrating superiority
- Balance development risks to optimize market access/label



Q & A



Thank you

Glossary

- ABSSSI: **A**cute **b**acterial **s**kin and **s**kin **s**tructure **i**nfections
- BARDA: **B**iomedical **A**dvanced **R**esearch and **D**evelopment **A**uthority
- CABP: **C**ommunity-acquired **b**acterial **p**neumonia
- EMA: **E**uropean **M**edicines **A**gency
- FDA: **U**S **F**ood and **D**rug **A**ministration
- HABP: **H**ospital-acquired **b**acterial **p**neumonia
- MSSA: **M**ethicillin-susceptible *Staphylococcus aureus*
- MRSA: **M**ethicillin-resistant *Staphylococcus aureus*
- NDA: **N**ew **D**rug **A**pplication
- QIDP: **Q**ualified **I**nfectious **D**isease **P**roduct
- SAB: *Staphylococcus aureus* **b**acteremia
- US GAAP: **U**nited **S**tates **G**enerally **A**ccepted **A**ccounting **P**inciples



Focused on Growth and Innovation

**Hegenheimermattweg 167b
4123 Allschwil
Switzerland**

**info@basilea.com
www.basilea.com**

All rights reserved.
© 2023 Basilea Pharmaceutica International Ltd, Allschwil